Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...

Akari Therapeutics ( ($AKTX) ) has issued an announcement. On March 14, 2025, Akari Therapeutics announced the appointment of Mr. Abizer ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...

Being hired during the offseason to take over a player development department can be a daunting task. That first Spring ...

Drafted as the first overall pick in the 2022 NBA Draft, Paolo Banchero is revolutionizing the role of a forward in basketball. With his ability to play almost any position from one to five on both ...

Where California's towering Sierra Nevada surrenders to the sprawling San Joaquin Valley, a high-stakes detective story is ...

Island Escape by Burasari, on Phuket’s Koh Maphrao or Coconut Island, is much-loved by travellers as a luxury all-inclusive ...

Prototype PGH Founder Erin Gatz saw a need to offer an on-ramp to manufacturing jobs to local people, rather than transplants ...

(Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...